TN-201 is under clinical development by Tenaya Therapeutics and currently in Phase I for Hypertrophic Cardiomyopathy. According to GlobalData, Phase I drugs for Hypertrophic Cardiomyopathy have a 93% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how TN-201’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
TN-201 overview
TN-201 is under development for the treatment of cardiomyopathy. It comprises of adeno-associated virus serotype 9 (AAV9) vectors to deliver cardiac myosin-binding protein-C gene (MYBPC3). It is developed based on Gene Therapy platform. It is administered through intravenous route.
Tenaya Therapeutics overview
Tenaya Therapeutics is a biopharmaceutical company that develops novel therapies to treat heart diseases. It utilizes its cellular regeneration, gene therapy, and precision medicine product platforms for drug development. Its product pipeline includes TN-201 to treat hypertrophic cardiomyopathy; TN-401 for treatment of cardiomyopathy; TN-301 targeting diastolic heart failure and dilated cardiomyopathy; and DWORF to treat congestive heart failure. Tenaya Therapeutics develops other drug candidates to treat dilated cardiomyopathy, heart failure, heart failure with preserved ejection fraction (HFrEF), hypertrophic cardiomyopathy, and genetic and idiopathic cardiomyopathies. The company works in collaboration with Gladstone Institutes and University of Texas Southwestern Medical Center. Tenaya Therapeutics is headquartered in South San Francisco, California, the US.
For a complete picture of TN-201’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
